GILD - Gilead Sciences Inc logo

GILD

Gilead Sciences Inc

Gilead Sciences is a biopharmaceutical company that discovers and develops medicines primarily for HIV, hepatitis B and C, and serious fungal infections. Its notable products include Biktarvy and Veklury, addressing significant unmet medical needs worldwide.

โš•๏ธ Healthcare NASDAQ Listed 1992 $ USD
$1,000 invested 30 years ago โ†’$309,006today

Score Overview

1 Year
Score
Net Growth-138.07%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth3.44%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.2
Net Growth-152.05%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth11.54%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-124.00%
Net Trend40%
Net Income Consistency
Rev Growth0.22%
Rev Trend60%
Revenue Consistency
20 Years
Score4.6
Net Growth-172.28%
Net Trend55%
Net Income Consistency
Rev Growth10x
Rev Trend75%
Revenue Consistency
30 Years
Score
Net Growth-147x
Net Trend57%
Net Income Consistency
Rev Growth911x
Rev Trend83%
Revenue Consistency
All Time
Score
Net Growth-227x
Net Trend56%
Net Income Consistency
Rev Growth7251x
Rev Trend79%
Revenue Consistency

See the full market ranking โ†’

Gilead Sciences Inc fundamental performance

Between 2005 and 2025, revenue grew from $ 2.02B to $ 29.44B and net income grew from $ 813M to $ 8.51B. Revenue increased in 15 of those 20 years; net income in 11.

Between 1995 and 2025, revenue grew from $ 2M to $ 29.44B and net income went from -$ 27M to $ 8.51B. Revenue increased in 25 of those 30 years; net income in 17.

Gilead Sciences Inc currently holds a 20-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 135.87โ€”
1 Year2025-08-12
$ 116.9716.16%
5 Years2021-08-12
$ 59.06130.07%
10 Years2016-08-12
$ 55.90143.04%
20 Years2006-08-11
$ 10.6512x
30 Years1996-08-12
$ 0.44309x
All Time1992-01-22
$ 0.43312x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 30.45B-$ 3.24B$ 3.17B
2025$ 29.44B$ 8.51B$ 9.61B
2024$ 28.75B$ 480M$ 11.56B
2023$ 27.11B$ 5.66B$ 7.26B
2022$ 27.28B$ 4.59B$ 6.38B
2021$ 27.30B$ 6.22B$ 6.52B
2020$ 24.68B$ 123M$ 7.40B
2019$ 22.44B$ 5.38B$ 24.35B
2018$ 22.12B$ 5.45B$ 30.08B
2017$ 26.10B$ 4.62B$ 25.51B
2016$ 30.39B$ 13.50B$ 32.38B
2015$ 32.63B$ 18.10B$ 26.20B
2014$ 24.89B$ 12.10B$ 11.72B
2013$ 11.20B$ 3.07B$ 2.13B
2012$ 9.70B$ 2.59B$ 1.86B
2011$ 8.38B$ 2.80B$ 9.90B
2010$ 7.94B$ 2.90B$ 2.09B
2009$ 7.01B$ 2.63B$ 1.65B
2008$ 5.33B$ 1.97B$ 1.79B
2007$ 4.23B$ 1.61B$ 1.17B
2006$ 3.02B-$ 1.18B$ 936M
2005$ 2.02B$ 813M$ 2.31B
2004$ 1.32B$ 449M$ 1.25B
2003$ 867M-$ 72M$ 707M
2002$ 466M$ 72M$ 942M
2001$ 233M$ 52M$ 582M
2000$ 195M-$ 56M$ 512M
1999$ 169M-$ 66M$ 294M
1998$ 151M-$ 44M$ 101M
1997$ 132M-$ 72M$ 32M
1996$ 33M-$ 21M$ 132M
1995$ 2M-$ 27M$ 27M
1994$ 4M-$ 31M$ 30M
1993$ 4M-$ 25M$ 13M
IPO1992$ 4M-$ 14M$ 2M

Explore beyond GILD

You're looking at Gilead Sciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies